Berkshire Hathaway Inc Valuation – April 2019 #BRK.B

Company Profile (excerpt from Reuters): Berkshire Hathaway Inc. (Berkshire), incorporated on June 16, 1998, is a holding company owning subsidiaries engaged in various business activities. The Company’s segments include Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy, Manufacturing, McLane Company, Service and retailing, and Finance and financial products. The Company conducts insurance businesses on both a primary basis and a reinsurance basis, a freight rail transportation business and a group of utility and energy generation and distribution businesses. Berkshire also owns and operates a range of other businesses engaged in a range of activities. Its insurance and reinsurance business activities are conducted through various domestic and foreign-based insurance entities. Its insurance businesses provide insurance and reinsurance of property and casualty risks and also reinsure life, accident and health risks across the world.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of BRK.B – April 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

 

Defensive Investor; must pass all 6 of the following tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $501,551,804,600 Pass
2. Earnings Stability Positive EPS for 10 years prior Pass
3. Dividend Record Dividend Payments for 10 years prior Fail
4. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 93.65% Pass
5. Moderate PEmg Ratio PEmg < 20 21.36 Fail
6. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 1.40 Pass
Enterprising Investor; must pass all 3 of the following tests, or be suitable for the Defensive Investor.
1. Earnings Stability Positive EPS for 5 years prior Pass
2. Dividend Record Currently Pays Dividend Fail
3. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $9.36
MG Growth Estimate 2.43%
MG Value $125.05
Opinion Overvalued
MG Grade F
MG Value based on 3% Growth $135.79
MG Value based on 0% Growth $79.60
Market Implied Growth Rate 6.43%
Current Price $200.07
% of Intrinsic Value 159.99%

Berkshire Hathaway Inc. Class B does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg ratio. The Enterprising Investor has concerns regarding the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $8.06 in 2015 to an estimated $9.36 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 6.43% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Berkshire Hathaway Inc. Class B revealed the company was trading above its Graham Number of $178.09. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 21.36, which was above the industry average of 19.43.

Berkshire Hathaway Inc. Class B scores quite poorly in the ModernGraham grading system, with an overall grade of F.

Stage 3: Information for Further Research

Graham Number $178.09
PEmg 21.36
PB Ratio 1.40
Dividend Yield 0.00%
TTM Dividend $0.00
Number of Consecutive Years of Dividend Growth 0

Useful Links:

 

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Long-Term Debt & Capital Lease Obligation $93,117,000,000
Total Assets $707,794,000,000
Intangible Assets $113,173,000,000
Total Liabilities $355,294,000,000
Shares Outstanding (Diluted Average) 2,462,433,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $10.00
Dec2018 $1.63
Dec2017 $18.22
Dec2016 $9.76
Dec2015 $9.77
Dec2014 $8.06
Dec2013 $7.90
Dec2012 $5.99
Dec2011 $4.14
Dec2010 $5.29
Dec2009 $3.46
Dec2008 $2.15
Dec2007 $5.70
Dec2006 $4.76
Dec2005 $3.69
Dec2004 $3.17
Dec2003 $3.54
Dec2002 $1.86
Dec2001 $0.35
Dec2000 $1.46
Dec1999 $0.68

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $9.36
Dec2018 $9.19
Dec2017 $12.23
Dec2016 $8.92
Dec2015 $8.06
Dec2014 $6.90
Dec2013 $5.99
Dec2012 $4.76
Dec2011 $4.15
Dec2010 $4.19
Dec2009 $3.75
Dec2008 $3.89
Dec2007 $4.57
Dec2006 $3.80
Dec2005 $3.06
Dec2004 $2.52
Dec2003 $1.99

Recommended Reading:

Other ModernGraham posts about the company

Berkshire Hathaway Inc Valuation – May 2018 $BRK-B
Berkshire Hathaway Inc Valuation – January 2017 $BRK.B
Berkshire Hathaway Analysis – August 2015 Update $BRK/B
20 Companies in the Spotlight This Week – 8/16/14

Other ModernGraham posts about related companies

Prudential Financial Inc Valuation – April 2019 #PRU
Torchmark Corp Valuation – March 2019 #TMK
Assurant Inc Valuation – March 2019 #AIZ
Humana Inc Valuation – March 2019 #HUM
American International Group Inc Valuation – March 2019 #AIG
Chubb Ltd Valuation – March 2019 #CB
Loews Corporation Valuation – March 2019 #L
Anthem Inc Valuation – February 2019 $ANTM
Arthur J Gallagher & Co Valuation – February 2019 $AJG
Brighthouse Financial Inc Valuation – February 2019 $BHF

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Broadridge Financial Solutions Inc Valuation – April 2019 #BR

Company Profile (excerpt from Reuters): Broadridge Financial Solutions, Inc. (Broadridge), incorporated on December 6, 2006, is a provider of investor communications and technology-driven solutions to banks, broker-dealers, mutual funds and corporate issuers. The Company’s segments include Investor Communication Solutions, and Global Technology and Operations. The Company’s services include investor and customer communications, securities processing, and data and analytics solutions. The Company delivers a range of solutions that helps its clients serve their retail and institutional customers across the entire investment lifecycle, including pre-trade, trade, and post-trade processing functionality. The Company serves a client base across four client groups: capital markets, asset management, wealth management and corporations.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of BR – April 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $12,145,347,942 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.02 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 185.25% Pass
6. Moderate PEmg Ratio PEmg < 20 31.08 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 11.13 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.02 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 78.56 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $3.37
MG Growth Estimate 11.73%
MG Value $107.83
Opinion Fairly Valued
MG Grade D
MG Value based on 3% Growth $48.93
MG Value based on 0% Growth $28.68
Market Implied Growth Rate 11.29%
Current Price $104.87
% of Intrinsic Value 97.25%

Broadridge Financial Solutions, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Fairly Valued after growing its EPSmg (normalized earnings) from $1.89 in 2015 to an estimated $3.37 for 2019. This level of demonstrated earnings growth supports the market’s implied estimate of 11.29% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value within a margin of safety relative to the price.

At the time of valuation, further research into Broadridge Financial Solutions, Inc. revealed the company was trading above its Graham Number of $29.75. The company pays a dividend of $1.46 per share, for a yield of 1.4% Its PEmg (price over earnings per share – ModernGraham) was 31.08, which was above the industry average of 21.66. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-10.65.

Broadridge Financial Solutions, Inc. scores quite poorly in the ModernGraham grading system, with an overall grade of D.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$10.65
Graham Number $29.75
PEmg 31.08
Current Ratio 1.02
PB Ratio 11.13
Current Dividend $1.46
Dividend Yield 1.39%
Number of Consecutive Years of Dividend Growth 12

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $966,400,000
Total Current Liabilities $951,200,000
Long-Term Debt $1,194,100,000
Total Assets $3,357,600,000
Intangible Assets $1,699,700,000
Total Liabilities $2,235,000,000
Shares Outstanding (Diluted Average) 119,100,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $4.18
Jun2018 $3.56
Jun2017 $2.70
Jun2016 $2.53
Jun2015 $2.32
Jun2014 $2.12
Jun2013 $1.69
Jun2012 $0.97
Jun2011 $1.32
Jun2010 $1.37
Jun2009 $1.58
Jun2008 $1.36
Jun2007 $1.42
Jun2006 $1.20

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $3.37
Jun2018 $2.86
Jun2017 $2.43
Jun2016 $2.18
Jun2015 $1.89
Jun2014 $1.62
Jun2013 $1.37
Jun2012 $1.25
Jun2011 $1.40
Jun2010 $1.42
Jun2009 $1.33
Jun2008 $1.07
Jun2007 $0.79
Jun2006 $0.40

Recommended Reading:

Other ModernGraham posts about the company

None. This is the first time ModernGraham has covered the company.

Other ModernGraham posts about related companies

T.Rowe Price Group Inc Valuation – March 2019 #TROW
Moody’s Corp Valuation – March 2019 #MCO
Charles Schwab Corp Valuation – March 2019 #SCHW
Willis Towers Watson PLC Valuation – March 2019 #WLTW
Paypal Holdings Inc Valuation – March 2019 #PYPL
Synchrony Financial Valuation – March 2019 #SYF
CBRE Group Inc Valuation – March 2019 #CBRE
Franklin Resources Inc Valuation – March 2019 #BEN
S&P Global Inc Valuation – March 2019 #SPGI
Equifax Inc Valuation – March 2019 #EFX

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Bristol-Myers Squibb Co Valuation – April 2019 #BMY

Company Profile (excerpt from Reuters): Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Downloadable PDF version of this valuation:

ModernGraham Valuation of BMY – April 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $76,654,092,495 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.61 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 51.08% Pass
6. Moderate PEmg Ratio PEmg < 20 17.33 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.44 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.61 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.87 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $2.71
MG Growth Estimate 15.00%
MG Value $104.21
Opinion Undervalued
MG Grade B
MG Value based on 3% Growth $39.25
MG Value based on 0% Growth $23.01
Market Implied Growth Rate 4.42%
Current Price $46.91
% of Intrinsic Value 45.02%

Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio. The Enterprising Investor has no initial concerns. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.24 in 2015 to an estimated $2.71 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.42% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into Bristol-Myers Squibb Co revealed the company was trading above its Graham Number of $28.16. The company pays a dividend of $1.61 per share, for a yield of 3.4%, putting it among the best dividend paying stocks today. Its PEmg (price over earnings per share – ModernGraham) was 17.33, which was below the industry average of 45.96, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-2.26.

Bristol-Myers Squibb Co performs fairly well in the ModernGraham grading system, scoring a B.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$2.26
Graham Number $28.16
PEmg 17.33
Current Ratio 1.61
PB Ratio 5.44
Current Dividend $1.61
Dividend Yield 3.43%
Number of Consecutive Years of Dividend Growth 12

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $17,160,000,000
Total Current Liabilities $10,654,000,000
Long-Term Debt $5,646,000,000
Total Assets $34,986,000,000
Intangible Assets $7,629,000,000
Total Liabilities $20,859,000,000
Shares Outstanding (Diluted Average) 1,637,000,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $4.10
Dec2018 $3.01
Dec2017 $0.61
Dec2016 $2.65
Dec2015 $0.93
Dec2014 $1.20
Dec2013 $1.54
Dec2012 $1.16
Dec2011 $2.16
Dec2010 $1.79
Dec2009 $5.34
Dec2008 $2.62
Dec2007 $1.09
Dec2006 $0.81
Dec2005 $1.52
Dec2004 $1.21
Dec2003 $1.59
Dec2002 $1.06
Dec2001 $0.95
Dec2000 $1.84
Dec1999 $1.81

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $2.71
Dec2018 $1.90
Dec2017 $1.36
Dec2016 $1.65
Dec2015 $1.24
Dec2014 $1.45
Dec2013 $1.85
Dec2012 $2.21
Dec2011 $2.69
Dec2010 $2.74
Dec2009 $2.91
Dec2008 $1.61
Dec2007 $1.15
Dec2006 $1.20
Dec2005 $1.35
Dec2004 $1.29
Dec2003 $1.37

Recommended Reading:

Other ModernGraham posts about the company

Bristol-Myers Squibb Company Valuation – June 2018 $BMY
Bristol-Myers Squibb Co Valuation – September 2017 $BMY
Bristol-Myers Squibb Company Valuation – February 2016 $BMY
27 Companies in the Spotlight This Week – 12/20/14
Bristol-Myers Squibb Company Annual Valuation – 2014 $BMY

Other ModernGraham posts about related companies

Biogen Inc Valuation – March 2019 #BIIB
Mylan NV Valuation – March 2019 #MYL
Celgene Corp Valuation – March 2019 #CELG
Amgen Inc Valuation – March 2019 #AMGN
AbbVie Inc Valuation – March 2019 #ABBV
Allergan PLC Valuation – February 2019 $AGN
Incyte Corp Valuation – February 2019 $INCY
Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN
Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN
Vertex Pharmaceuticals Inc Valuation – February 2019 $VRTX

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Fortune Brands Home & Security Inc Valuation – March 2019 #FBHS

Company Profile (excerpt from Reuters): Fortune Brands Home & Security, Inc., incorporated on June 9, 1988, is a holding company. The Company is a home and security products company. The Company operates through four segments: Cabinets, Plumbing, Doors and Security. The Company sells its products through a range of sales channels, including kitchen and bath dealers, wholesalers oriented toward builders or professional remodelers, industrial and locksmith distributors, do-it-yourself remodeling-oriented home centers and other retail outlets. The Company’s subsidiaries include MasterBrand Cabinets, Inc., Moen Incorporated, Fortune Brands Global Plumbing Group LLC, Fortune Brands Doors, Inc. and Fortune Brands Storage & Security LLC.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of FBHS – March 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $6,456,820,866 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.13 Fail
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 915.73% Pass
6. Moderate PEmg Ratio PEmg < 20 15.79 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 3.00 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.13 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 9.32 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $2.91
MG Growth Estimate 15.00%
MG Value $112.04
Opinion Undervalued
MG Grade C-
MG Value based on 3% Growth $42.20
MG Value based on 0% Growth $24.74
Market Implied Growth Rate 3.64%
Current Price $45.94
% of Intrinsic Value 41.01%

Fortune Brands Home & Security Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.24 in 2015 to an estimated $2.91 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 3.64% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into Fortune Brands Home & Security Inc revealed the company was trading above its Graham Number of $34.08. The company pays a dividend of $0.8 per share, for a yield of 1.7% Its PEmg (price over earnings per share – ModernGraham) was 15.79, which was below the industry average of 24.02, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-14.73.

Fortune Brands Home & Security Inc receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$14.73
Graham Number $34.08
PEmg 15.79
Current Ratio 1.13
PB Ratio 3.00
Current Dividend $0.80
Dividend Yield 1.74%
Number of Consecutive Years of Dividend Growth 6

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $1,686,100,000
Total Current Liabilities $1,492,100,000
Long-Term Debt $1,809,000,000
Total Assets $5,964,600,000
Intangible Assets $3,327,100,000
Total Liabilities $3,784,600,000
Shares Outstanding (Diluted Average) 142,500,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $3.35
Dec2018 $2.66
Dec2017 $3.03
Dec2016 $2.62
Dec2015 $1.93
Dec2014 $0.95
Dec2013 $1.34
Dec2012 $0.71
Dec2011 -$0.23
Dec2010 $0.41

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $2.91
Dec2018 $2.54
Dec2017 $2.31
Dec2016 $1.80
Dec2015 $1.24
Dec2014 $0.81
Dec2013 $0.64
Dec2012 $0.26
Dec2011 $0.03
Dec2010 $0.14

Recommended Reading:

Other ModernGraham posts about the company

Fortune Brands Home & Security Inc Valuation – June 2018 $FBHS
6 Best Stocks for Value Investors This Week – 3/11/17
Fortune Brands Home & Security Inc Valuation – Initial Coverage $FBHS

Other ModernGraham posts about related companies

Fortune Brands Home & Security Inc Valuation – June 2018 $FBHS
Tyco International PLC Valuation – November 2015 Update $TYC
ADT Stock Analysis – 2015 Annual Update $ADT
Tyco International Limited Annual Valuation – 2014 $TYC
ADT Corporation 2014 Annual Valuation $ADT

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

CBRE Group Inc Valuation – March 2019 #CBRE

Company Profile (excerpt from Reuters): CBRE Group, Inc., incorporated on February 20, 2001, is a holding company that conducts all of its operations through its subsidiaries. The Company operates as a commercial real estate services and investment company. The Company operates through the segments: The Americas; Europe, Middle East and Africa (EMEA); Asia Pacific; Global Investment Management, and Development Services. The Company provides services in the office, retail, industrial, multifamily and hotel sectors of commercial real estate.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of CBRE – March 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $16,848,841,335 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.16 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 270.51% Pass
6. Moderate PEmg Ratio PEmg < 20 18.28 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 3.43 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.16 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.86 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $2.74
MG Growth Estimate 15.00%
MG Value $105.64
Opinion Undervalued
MG Grade C-
MG Value based on 3% Growth $39.79
MG Value based on 0% Growth $23.32
Market Implied Growth Rate 4.89%
Current Price $50.16
% of Intrinsic Value 47.48%

CBRE Group Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history, and the high PB ratio. The Enterprising Investor has concerns regarding the level of debt relative to the current assets, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.3 in 2015 to an estimated $2.74 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.89% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into CBRE Group Inc revealed the company was trading above its Graham Number of $33.87. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 18.28, which was below the industry average of 21.22, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-4.94.

CBRE Group Inc receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$4.94
Graham Number $33.87
PEmg 18.28
Current Ratio 1.16
PB Ratio 3.43
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $6,754,210,000
Total Current Liabilities $5,803,380,000
Long-Term Debt $1,767,260,000
Total Assets $13,456,793,000
Intangible Assets $5,093,617,000
Total Liabilities $8,446,891,000
Shares Outstanding (Diluted Average) 342,689,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $3.52
Dec2018 $3.10
Dec2017 $2.05
Dec2016 $1.69
Dec2015 $1.63
Dec2014 $1.45
Dec2013 $0.95
Dec2012 $0.97
Dec2011 $0.74
Dec2010 $0.63
Dec2009 $0.12
Dec2008 -$4.81
Dec2007 $1.66
Dec2006 $1.35
Dec2005 $0.95
Dec2004 $0.30
Dec2003 -$0.23
Dec2002 $0.15
Dec2001 $0.73

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $2.74
Dec2018 $2.23
Dec2017 $1.72
Dec2016 $1.48
Dec2015 $1.30
Dec2014 $1.07
Dec2013 $0.82
Dec2012 $0.34
Dec2011 -$0.09
Dec2010 -$0.41
Dec2009 -$0.67
Dec2008 -$0.74
Dec2007 $1.13
Dec2006 $0.74
Dec2005 $0.42
Dec2004 $0.17
Dec2003 $0.11

Recommended Reading:

Other ModernGraham posts about the company

CBRE Group Inc Valuation – June 2018 $CBRE

Other ModernGraham posts about related companies

Franklin Resources Inc Valuation – March 2019 #BEN
S&P Global Inc Valuation – March 2019 #SPGI
Equifax Inc Valuation – March 2019 #EFX
CME Group Inc Valuation – March 2019 #CME
Northern Trust Corp Valuation – March 2019 #NTRS
Affiliated Managers Group Inc Valuation – February 2019 $AMG
Bank of New York Mellon Corp Valuation – February 2019 $BK
Western Union Co Valuation – February 2019 $WU
Raymond James Financial Valuation – February 2019 $RJF
Nasdaq Inc Valuation – February 2019 $NDAQ

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Brown-Forman Corp Valuation – March 2019 #BF.B

Company Profile (excerpt from Reuters): Brown-Forman Corporation, incorporated on October 19, 1933, is a spirit and wine company. The Company manufactures, bottles, imports, exports, markets and sells a range of alcoholic beverages. The Company has a portfolio of approximately 40 spirit, wine and ready-to-drink cocktail (RTD) brands. The Company’s principal brands include Jack Daniel’s Tennessee Whiskey, Jack Daniel’s RTDs, Jack Daniel’s Tennessee Honey, Gentleman Jack Rare Tennessee Whiskey, Jack Daniel’s Tennessee Fire, Jack Daniel’s Single Barrel Collection, Jack Daniel’s Sinatra Select, Jack Daniel’s Winter Jack, Jack Daniel’s No. 27 Gold Tennessee Whiskey, Finlandia Vodkas, Finlandia RTDs, Korbel California Champagnes, Korbel California Brandy, Woodford Reserve Kentucky Bourbons, el Jimador Tequilas, el Jimador New Mix RTDs, Herradura Tequilas, Canadian Mist Canadian Whisky, Sonoma-Cutrer California Wines, Early Times Kentucky Whisky and Bourbon, Chambord Liqueur, Old Forester Kentucky Bourbon, Antiguo Tequila, Pepe Lopez Tequila, Santa Dose Cachaca and Collingwood Canadian Whisky.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of BF.B – March 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

 

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $24,015,987,587 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 3.08 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 60.76% Pass
6. Moderate PEmg Ratio PEmg < 20 31.88 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 16.19 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 3.08 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.24 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $1.58
MG Growth Estimate 5.27%
MG Value $30.07
Opinion Overvalued
MG Grade C+
MG Value based on 3% Growth $22.90
MG Value based on 0% Growth $13.42
Market Implied Growth Rate 11.69%
Current Price $50.35
% of Intrinsic Value 167.46%

Brown-Forman Corporation Class B is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the high PEmg and PB ratios. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $1.17 in 2015 to an estimated $1.58 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 11.69% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Brown-Forman Corporation Class B revealed the company was trading above its Graham Number of $10.05. The company pays a dividend of $0.61 per share, for a yield of 1.2% Its PEmg (price over earnings per share – ModernGraham) was 31.88, which was above the industry average of 22.75. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-1.91.

Brown-Forman Corporation Class B receives an average overall rating in the ModernGraham grading system, scoring a C+.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$1.91
Graham Number $10.05
PEmg 31.88
Current Ratio 3.08
PB Ratio 16.19
Current Dividend $0.61
Dividend Yield 1.21%
Number of Consecutive Years of Dividend Growth 20

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 1/1/2019
Total Current Assets $2,755,000,000
Total Current Liabilities $895,000,000
Long-Term Debt $2,301,000,000
Total Assets $5,163,000,000
Intangible Assets $1,405,000,000
Total Liabilities $3,670,000,000
Shares Outstanding (Diluted Average) 480,099,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $1.64
Apr2018 $1.48
Apr2017 $1.37
Apr2016 $2.09
Apr2015 $1.28
Apr2014 $1.22
Apr2013 $1.10
Apr2012 $0.95
Apr2011 $1.04
Apr2010 $0.81
Apr2009 $0.77
Apr2008 $0.76
Apr2007 $0.67
Apr2006 $0.55
Apr2005 $0.54
Apr2004 $0.43
Apr2003 $0.35
Apr2002 $0.35
Apr2001 $0.36
Apr2000 $0.34
Apr1999 $0.31

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $1.58
Apr2018 $1.53
Apr2017 $1.51
Apr2016 $1.49
Apr2015 $1.17
Apr2014 $1.08
Apr2013 $0.99
Apr2012 $0.91
Apr2011 $0.86
Apr2010 $0.75
Apr2009 $0.70
Apr2008 $0.64
Apr2007 $0.56
Apr2006 $0.48
Apr2005 $0.43
Apr2004 $0.38
Apr2003 $0.35

Recommended Reading:

Other ModernGraham posts about the company

Brown-Forman Corp Valuation – May 2018 $BF.B
Brown-Forman Corporation – February 2017 $BF.B
5 Speculative and Overvalued Companies to Avoid – November 2015
Brown-Forman Corporation Analysis – September 2015 Update $BF/B
Brown-Forman Corporation Analysis – June 2015 Update $BF.B

Other ModernGraham posts about related companies

Constellation Brands Inc Valuation – March 2019 #STZ
Philip Morris International Inc Valuation – January 2019 $PM
Altria Group Inc Valuation – January 2019 $MO
Molson Coors Brewing Co Valuation – January 2019 $TAP
Boston Beer Company Inc Valuation – July 2018 $SAM
Constellation Brands Inc Valuation – May 2018 $STZ
Brown-Forman Corp Valuation – May 2018 $BF.B
Philip Morris International Inc Valuation – March 2018 $PM
Altria Group Inc Valuation – March 2018 $MO
Molson Coors Brewing Co Valuation – March 2018 $TAP

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Constellation Brands Inc Valuation – March 2019 #STZ

Company Profile (excerpt from Reuters): Constellation Brands, Inc., incorporated on December 4, 1972, is an international beverage alcohol company. The Company is a producer and marketer of beer, wine and spirits with operations in the United States, Canada, Mexico, New Zealand and Italy. The Company’s segments include Beer, Wine and Spirits, and Corporate Operations and Other. The Company’s wine portfolio is complemented by select spirits brands and other select beverage alcohol products. It is a multi-category supplier (beer, wine and spirits) of beverage alcohol in the United States.

STZ Chart

STZ data by YCharts

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of STZ – March 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $31,587,195,102 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.08 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 514.04% Pass
6. Moderate PEmg Ratio PEmg < 20 16.86 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.81 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.08 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 42.79 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $9.84
MG Growth Estimate 15.00%
MG Value $378.81
Opinion Undervalued
MG Grade C-
MG Value based on 3% Growth $142.67
MG Value based on 0% Growth $83.63
Market Implied Growth Rate 4.18%
Current Price $165.91
% of Intrinsic Value 43.80%

Constellation Brands, Inc. Class A does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $4.88 in 2015 to an estimated $9.84 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.18% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into Constellation Brands, Inc. Class A revealed the company was trading above its Graham Number of $110.32. The company pays a dividend of $2.08 per share, for a yield of 1.3% Its PEmg (price over earnings per share – ModernGraham) was 16.86, which was below the industry average of 22.75, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-65.35.

Constellation Brands, Inc. Class A receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$65.35
Graham Number $110.32
PEmg 16.86
Current Ratio 1.08
PB Ratio 2.81
Current Dividend $2.08
Dividend Yield 1.25%
Number of Consecutive Years of Dividend Growth 3

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 11/1/2018
Total Current Assets $3,638,500,000
Total Current Liabilities $3,363,400,000
Long-Term Debt $11,772,500,000
Total Assets $27,890,400,000
Intangible Assets $11,369,600,000
Total Liabilities $16,370,400,000
Shares Outstanding (Diluted Average) 194,820,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $12.86
Feb2018 $11.55
Feb2017 $7.52
Feb2016 $5.18
Feb2015 $4.17
Feb2014 $9.83
Feb2013 $2.04
Feb2012 $2.13
Feb2011 $2.62
Feb2010 $0.45
Feb2009 -$1.40
Feb2008 -$2.83
Feb2007 $1.38
Feb2006 $1.36
Feb2005 $1.19
Feb2004 $1.03
Feb2003 $1.10
Feb2002 $0.78
Feb2001 $0.65
Feb2000 $0.53
Feb1999 $0.34

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $9.84
Feb2018 $8.10
Feb2017 $6.17
Feb2016 $5.22
Feb2015 $4.88
Feb2014 $4.63
Feb2013 $1.74
Feb2012 $1.12
Feb2011 $0.43
Feb2010 -$0.51
Feb2009 -$0.68
Feb2008 -$0.08
Feb2007 $1.27
Feb2006 $1.17
Feb2005 $1.04
Feb2004 $0.91
Feb2003 $0.79

Recommended Reading:

Other ModernGraham posts about the company

5 Undervalued Companies for Value Investors with a Low Beta – January 2019
Constellation Brands Inc Valuation – May 2018 $STZ
Constellation Brands Inc Valuation – February 2017 $STZ
Constellation Brands Inc Valuation – August 2016 $STZ
19 Best Stocks For Value Investors This Week – 1/9/16

Other ModernGraham posts about related companies

Philip Morris International Inc Valuation – January 2019 $PM
Altria Group Inc Valuation – January 2019 $MO
Molson Coors Brewing Co Valuation – January 2019 $TAP
Boston Beer Company Inc Valuation – July 2018 $SAM
Constellation Brands Inc Valuation – May 2018 $STZ
Brown-Forman Corp Valuation – May 2018 $BF.B
Philip Morris International Inc Valuation – March 2018 $PM
Altria Group Inc Valuation – March 2018 $MO
Molson Coors Brewing Co Valuation – March 2018 $TAP
Molson Coors Brewing Co Valuation – Initial Coverage $TAP

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Anthem Inc Valuation – February 2019 $ANTM

Company Profile (excerpt from Reuters): Anthem, Inc., incorporated on July 17, 2001, is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a full spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations (PPOs); health maintenance organizations (HMOs); point-of-service (POS), plans; indemnity plans and other hybrid plans, including consumer-driven health plans (CDHPs); and hospital only and limited benefit products. In addition, it provides an array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. It provides an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. It also provides services to the federal government in connection with the Federal Employee Program (FEP).

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of ANTM – February 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass all 6 of the following tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $77,501,965,462 Pass
2. Earnings Stability Positive EPS for 10 years prior Pass
3. Dividend Record Dividend Payments for 10 years prior Fail
4. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 104.74% Pass
5. Moderate PEmg Ratio PEmg < 20 21.15 Fail
6. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.79 Fail
Enterprising Investor; must pass all 3 of the following tests, or be suitable for the Defensive Investor.
1. Earnings Stability Positive EPS for 5 years prior Pass
2. Dividend Record Currently Pays Dividend Pass
3. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $14.26
MG Growth Estimate 9.48%
MG Value $391.61
Opinion Fairly Valued
MG Grade C+
MG Value based on 3% Growth $206.78
MG Value based on 0% Growth $121.22
Market Implied Growth Rate 6.32%
Current Price $301.55
% of Intrinsic Value 77.00%

Anthem Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor has no initial concerns. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Fairly Valued after growing its EPSmg (normalized earnings) from $8.74 in 2015 to an estimated $14.26 for 2019. This level of demonstrated earnings growth supports the market’s implied estimate of 6.32% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value within a margin of safety relative to the price.

At the time of valuation, further research into Anthem Inc revealed the company was trading above its Graham Number of $207.01. The company pays a dividend of $3 per share, for a yield of 1% Its PEmg (price over earnings per share – ModernGraham) was 21.15, which was below the industry average of 32.96, which by some methods of valuation makes it one of the most undervalued stocks in its industry.

Anthem Inc receives an average overall rating in the ModernGraham grading system, scoring a C+.

Stage 3: Information for Further Research

Graham Number $207.01
PEmg 21.15
PB Ratio 2.79
Dividend Yield 0.99%
TTM Dividend $3.00
Number of Consecutive Years of Dividend Growth 8

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Long-Term Debt & Capital Lease Obligation $17,217,000,000
Total Assets $71,571,000,000
Intangible Assets $29,511,000,000
Total Liabilities $43,030,000,000
Shares Outstanding (Diluted Average) 263,900,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $17.26
Dec2018 $14.19
Dec2017 $14.35
Dec2016 $9.21
Dec2015 $9.38
Dec2014 $8.99
Dec2013 $8.20
Dec2012 $8.18
Dec2011 $7.25
Dec2010 $6.94
Dec2009 $9.88
Dec2008 $4.76
Dec2007 $5.56
Dec2006 $4.82
Dec2005 $3.94
Dec2004 $3.05
Dec2003 $2.73
Dec2002 $2.26
Dec2001 $1.65

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $14.26
Dec2018 $12.25
Dec2017 $10.86
Dec2016 $9.01
Dec2015 $8.74
Dec2014 $8.25
Dec2013 $7.95
Dec2012 $7.68
Dec2011 $7.25
Dec2010 $6.96
Dec2009 $6.58
Dec2008 $4.76
Dec2007 $4.52
Dec2006 $3.78
Dec2005 $3.08
Dec2004 $2.42
Dec2003 $1.84

Recommended Reading:

Other ModernGraham posts about the company

Anthem Inc Valuation – May 2018 $ANTM
Anthem Inc Valuation – January 2017 $ANTM
15 Best Undervalued Stocks of the Week – 8/20/16
Anthem Inc Valuation – August 2016 $ANTM
15 Best Stocks For Value Investors This Week – 2/13/16

Other ModernGraham posts about related companies

Arthur J Gallagher & Co Valuation – February 2019 $AJG
Brighthouse Financial Inc Valuation – February 2019 $BHF
Allstate Corp Valuation – February 2019 $ALL
Hartford Financial Services Group Inc Valuation – February 2019 $HIG
Unum Group Valuation – February 2019 $UNM
Everest Re Group Ltd Valuation – February 2019 $RE
Cigna Corp Valuation – January 2019 $CI
MetLife Inc Valuation – January 2019 $MET
Aflac Inc Valuation – January 2019 $AFL
Principal Financial Group Inc Valuation – January 2019 $PFG

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Abbott Laboratories Valuation – February 2019 $ABT

Company Profile (excerpt from Reuters): Abbott Laboratories, incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Company, through St. Jude Medical, Inc., also offers a range of products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of ABT – February 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $136,723,618,367 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.62 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end -50.67% Fail
6. Moderate PEmg Ratio PEmg < 20 43.49 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 4.49 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.62 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 3.44 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Fail

 

Stage 2: Determination of Intrinsic Value

EPSmg $1.79
MG Growth Estimate -3.78%
MG Value $1.68
Opinion Overvalued
MG Grade D
MG Value based on 3% Growth $25.94
MG Value based on 0% Growth $15.20
Market Implied Growth Rate 17.50%
Current Price $77.79
% of Intrinsic Value 4629.78%

Abbott Laboratories does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the net current assets, and the lack of earnings growth over the last five years. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after seeing its EPSmg (normalized earnings) decline from $2.39 in 2015 to an estimated $1.79 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 17.5% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Abbott Laboratories revealed the company was trading above its Graham Number of $35.26. The company pays a dividend of $1.12 per share, for a yield of 1.4% Its PEmg (price over earnings per share – ModernGraham) was 43.49, which was below the industry average of 51.18, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-12.3.

Abbott Laboratories scores quite poorly in the ModernGraham grading system, with an overall grade of D.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$12.30
Graham Number $35.26
PEmg 43.49
Current Ratio 1.62
PB Ratio 4.49
Current Dividend $1.12
Dividend Yield 1.44%
Number of Consecutive Years of Dividend Growth 5

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $14,632,000,000
Total Current Liabilities $9,012,000,000
Long-Term Debt $19,359,000,000
Total Assets $67,173,000,000
Intangible Assets $42,196,000,000
Total Liabilities $36,451,000,000
Shares Outstanding (Diluted Average) 1,773,870,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $3.18
Dec2018 $1.33
Dec2017 $0.27
Dec2016 $0.94
Dec2015 $2.92
Dec2014 $1.49
Dec2013 $1.62
Dec2012 $3.72
Dec2011 $3.01
Dec2010 $2.96
Dec2009 $3.69
Dec2008 $3.12
Dec2007 $2.31
Dec2006 $1.12
Dec2005 $2.16
Dec2004 $2.06
Dec2003 $1.75
Dec2002 $1.78
Dec2001 $0.99
Dec2000 $1.78
Dec1999 $1.57

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $1.79
Dec2018 $1.19
Dec2017 $1.23
Dec2016 $1.85
Dec2015 $2.39
Dec2014 $2.27
Dec2013 $2.77
Dec2012 $3.33
Dec2011 $3.10
Dec2010 $2.98
Dec2009 $2.82
Dec2008 $2.31
Dec2007 $1.89
Dec2006 $1.71
Dec2005 $1.92
Dec2004 $1.76
Dec2003 $1.60

Recommended Reading:

Other ModernGraham posts about the company

10 Most Overvalued Stocks of the S&P 500 – July 2018
Abbott Laboratories Valuation – May 2018 $ABT
Abbott Laboratories Valuation – January 2017 $ABT
Abbott Laboratories Valuation – August 2016 $ABT
5 Speculative and Overvalued Companies to Avoid – March 2015

Other ModernGraham posts about related companies

Becton Dickinson and Co Valuation – February 2019 $BDX
IQVIA Holdings Inc Valuation – February 2019 $IQV
Thermo Fisher Scientific Inc Valuation – February 2019 $TMO
Illumina Inc Valuation – February 2019 $ILMN
Waters Corp Valuation – February 2019 $WAT
Cerner Corp Valuation – February 2019 $CERN
HCA Healthcare Inc Valuation – February 2019 $HCA
Stryker Corp Valuation – February 2019 $SYK
Align Technology Inc Valuation – February 2019 $ALGN
Quest Diagnostics Inc Valuation – February 2019 $DGX

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

PPG Industries Inc Valuation – February 2019 $PPG

Company Profile (excerpt from Reuters): PPG Industries, Inc., incorporated on August 24, 1883, manufactures and distributes a range of coatings and specialty materials. The Company has two segments: Performance Coatings and Industrial Coatings. The Company’s geographical segments include the United States, Canada, Western Europe, Latin America, Central and Eastern Europe, the Middle East, Africa and Asia Pacific. The Company’s brands include PPG, GLIDDEN, COMEX, OLYMPIC, DULUX (in Canada), SIKKENS, PPG PITTSBURGH PAINTS, MULCO, FLOOD, LIQUID NAILS, SICO, CIL, RENNER, TAUBMANS, WHITE KNIGHT, BRISTOL, HOMAX, SIGMA, HISTOR, SEIGNEURIE, GUITTET, PEINTURES GAUTHIER, RIPOLIN, JOHNSTONE’S, LEYLAND, PRIMALEX, DEKORAL, TRILAK, PROMINENT PAINTS, GORI and BONDEX.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of PPG – February 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $26,373,508,919 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.36 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 102.28% Pass
6. Moderate PEmg Ratio PEmg < 20 20.29 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.66 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.36 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 2.75 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Fail

 

Stage 2: Determination of Intrinsic Value

EPSmg $5.51
MG Growth Estimate -2.43%
MG Value $20.00
Opinion Overvalued
MG Grade C-
MG Value based on 3% Growth $79.90
MG Value based on 0% Growth $46.84
Market Implied Growth Rate 5.90%
Current Price $111.80
% of Intrinsic Value 558.89%

PPG Industries, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the current assets, and the lack of earnings growth over the last five years. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after seeing its EPSmg (normalized earnings) decline from $6.58 in 2015 to an estimated $5.51 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 5.9% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into PPG Industries, Inc. revealed the company was trading above its Graham Number of $51.51. The company pays a dividend of $1.86 per share, for a yield of 1.7% Its PEmg (price over earnings per share – ModernGraham) was 20.29, which was below the industry average of 22.8, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-22.2.

PPG Industries, Inc. receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$22.20
Graham Number $51.51
PEmg 20.29
Current Ratio 1.36
PB Ratio 5.66
Current Dividend $1.86
Dividend Yield 1.66%
Number of Consecutive Years of Dividend Growth 20

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $5,961,000,000
Total Current Liabilities $4,373,000,000
Long-Term Debt $4,365,000,000
Total Assets $16,015,000,000
Intangible Assets $6,042,000,000
Total Liabilities $11,283,000,000
Shares Outstanding (Diluted Average) 239,700,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $6.11
Dec2018 $5.47
Dec2017 $6.18
Dec2016 $3.27
Dec2015 $5.14
Dec2014 $7.52
Dec2013 $11.13
Dec2012 $3.03
Dec2011 $3.44
Dec2010 $2.32
Dec2009 $1.02
Dec2008 $1.63
Dec2007 $2.52
Dec2006 $2.14
Dec2005 $1.75
Dec2004 $1.98
Dec2003 $1.45
Dec2002 -$0.21
Dec2001 $1.15
Dec2000 $1.79
Dec1999 $1.62

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $5.51
Dec2018 $5.31
Dec2017 $5.70
Dec2016 $5.65
Dec2015 $6.58
Dec2014 $6.69
Dec2013 $5.58
Dec2012 $2.63
Dec2011 $2.35
Dec2010 $1.85
Dec2009 $1.68
Dec2008 $2.00
Dec2007 $2.12
Dec2006 $1.75
Dec2005 $1.45
Dec2004 $1.27
Dec2003 $1.00

Recommended Reading:

Other ModernGraham posts about the company

PPG Industries Inc Valuation – May 2018 $PPG
PPG Industries Inc Valuation – January 2017 $PPG
5 Companies for Enterprising Investors Near 52 Week Lows – January 2017
Best Dividend Paying Stocks for Dividend Growth Investors – December 2016
5 Companies for Enterprising Investors Near 52 Week Lows – December 2016

Other ModernGraham posts about related companies

Celanese Corporation Valuation – February 2019 $CE
Ecolab Inc Valuation – January 2019 $ECL
FMC Corp Valuation – January 2019 $FMC
Air Products & Chemicals Inc Valuation – January 2019 $APD
Albemarle Corp Valuation – January 2019 $ALB
LyondellBasell Industries NV Valuation – January 2019 $LYB
Eastman Chemical Co Valuation – January 2019 $EMN
DowDuPont Inc Valuation – November 2018 $DWDP
Chemtrade Logistics Income Fund Valuation – July 2018 $TSE:CHE.UN
PPG Industries Inc Valuation – May 2018 $PPG

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Back To Top